Binding Peptides Having a C-terminally Disposed Specific Binding Domain

• US 20090148447A1
• Filed: 07/07/2008
• Published: 06/11/2009
• Est. Priority Date: 07/06/2007
• Status: Abandoned Application

• Current Assignee: Emergent Product Development Seattle, LLC
• Original Assignee: Trubion Pharmaceuticals Inc.
• Inventors: Ledbetter, Jeffrey A., Brady, William
• Application Number:
  US12/168,875
• Publication Number:
  US 20090148447A1
• Time in Patent Office: Days
• US Class Current: 424/134.100
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 16/2833 against MHC-molecules, e.g. HLA-molecules
• CPC Class Codes: C07K 16/2887 against CD20
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/53 Hinge
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/734 Complement-dependent cytotoxicity [CDC]
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

Specific binding peptides having a general schematized structure of an optional N-terminal hinge region joined to an immunoglobulin-derived constant sub-region comprising a C_H2 region and a C_H3 region, followed by a PIMS linker peptide and at least one specific binding domain are provided, along with encoding nucleic acids, vectors and host cells. Also provided are methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.

Claims

1. A specific binding protein comprising:

a constant sub-region derived from an antibody;

a PIMS linker disposed C-terminal to the constant sub-region; and

a specific binding domain comprising at least one of a V_L domain and a V_H domain, the specific binding domain disposed C-terminal to the PIMS linker, wherein the specific binding protein specifically binds at least one target and exhibits at least one effector function of an antibody molecule.

2. The specific binding protein according to claim 1 wherein the constant sub-region comprises a C_H2 domain and a C_H3 domain, wherein at least one of the C_H2 domain and the C_H3 domain is a complete antibody domain.

3. The specific binding protein according to claim 2 wherein the antibody domain is selected from the group consisting of IgG, IgE, IgD, IgA and IgM antibody domains.

4. The specific binding protein according to claim 2 wherein at least one of the C_H2 domain and the C_H3 domain comprises a sequence selected from the group consisting of SEQ ID NO:

377 and SEQ ID NO;

379.

5. The specific binding protein according to claim 1 wherein the effector function is antibody-dependent cellular cytotoxicity or complement-mediated cytotoxicity.

6. The specific binding protein according to claim 1 wherein the PIMS linker is derived from a stalk region of a type II C-lectin.

7. The specific binding protein according to claim 1 wherein the PIMS linker is selected from the group consisting of an antibody hinge region, a CD72 stalk region, NKG2a and NKG2a C18S.

8. The specific binding protein according to claim 1 wherein the PIMS linker is an antibody hinge region selected from the group consisting of IgG, IgA, IgD, IgE hinges and variants thereof.

9. The specific binding protein according to claim 8 wherein the hinge is an antibody hinge region selected from the group consisting of human IgG1, human IgG2, human IgG3, human IgG4, and human variants thereof.

10. The specific binding protein according to claim 1 wherein the PIMS linker has a single cysteine residue for formation of an interchain disulfide bond.

11. The specific binding protein according to claim 1 wherein the PIMS linker has two cysteine residues for formation of interchain disulfide bonds.

12. The specific binding protein according to claim 1 wherein the PIMS linker comprises a sequence selected from the group consisting of SEQ ID NOS:

61-118.

13. The specific binding protein according to claim 1 wherein the protein specifically binds a target selected from the group consisting of CD3, CD19, CD20, CD28, CD37 and DR.

14. The specific binding protein according to claim 1 wherein the protein is selected from the group consisting of W0001, W0002, W0003, W0004, W0005, W0006, W0007, W0008, W0009, W0011, W0012, W0023, W0024, W0025, W0028, W0029, W0030, W0031, W0035, W0036, W0041, W0042, W0044, W0045, W0050, W0051, W0052, W0053, W0055, W0056, W0057, W0083, W0087, W0094, W0095, W0096 and W0097.

15. The specific binding protein according to claim 1 wherein the V_L domain and the V_H domain are separated by an interdomain linker.

16. The specific binding protein according to claim 15 wherein the structure of the interdomain linker is (Gly₄Ser)_n, where n=1-5.

17. The specific binding protein according to claim 15 wherein the interdomain linker comprises a sequence selected from the group consisting of SEQ ID NO:

544, SEQ ID NO;

545, SEQ ID NO;

184, SEQ ID NO;

240, SEQ ID NO;

242, SEQ ID NO;

243, SEQ ID NO;

245, SEQ ID NO;

247, SEQ ID NO;

248, SEQ ID NO;

539 and SEQ ID NO;

540.

18. The specific binding protein according to claim 1 wherein at least one of the V_L domain and the V_H domain comprises a sequence selected from the group consisting of residues 23-128 of SEQ ID NO:

2, residues 145-265 of SEQ ID NO;

2, residues 520-640 of SEQ ID NO;

2, residues 661-772 of SEQ ID NO;

2, residues 508-629 of SEQ ID NO;

28, residues 647-754 of SEQ ID NO;

28, residues 508-629 of SEQ ID NO;

30, residues 652-759 of SEQ ID NO;

30, residues 21-127 of SEQ ID NO;

44, residues 143-264 of SEQ ID NO;

44, residues 1-121 of SEQ ID NO;

354 and residues 134-239 of SEQ ID NO;

354.

19. The specific binding protein according to claim 1 further comprising a hinge disposed N-terminal to the sub-region.

20. The specific binding protein according to claim 19 wherein the hinge comprises the same sequence as the PIMS linker disposed between the constant sub-region and the specific binding domain.

21. The specific binding protein according to claim 1, further comprising at least a second specific binding domain disposed C-terminal to the constant sub-region.

22. The specific binding protein according to claim 21, wherein each of the specific binding domains binds to the same target.

23. A method of producing the specific binding protein according to claim 1 comprising:

contacting a cell comprising a polynucleotide encoding the specific binding protein according to claim 1 and a culture medium; and

incubating the cell in the culture medium under conditions suitable for expression of the polynucleotide.

24. A method of treating a condition selected from the group consisting of cancer, inflammation and an autoimmune disorder comprising administering an effective amount of a specific binding protein according to claim 1 to an organism in need.

25. The method according to claim 24 wherein the organism is a human.

26. A method of ameliorating a symptom of a condition selected from the group consisting of cancer, inflammation and an autoimmune disorder comprising administering an effective amount of a specific binding protein according to claim 1 to an organism in need.

27. The method according to claim 26 wherein the organism is a human.

28. A use of a specific binding protein according to claim 1 in the preparation of a medicament for the treatment of a condition selected from the group consisting of cancer, inflammation and an autoimmune disorder.

29. The use according to claim 28 wherein the organism is a human.

30. A use of a specific binding protein according to claim 1 in the preparation of a medicament for ameliorating a symptom of a condition selected from the group consisting of cancer, inflammation and an autoimmune disorder.

31. The use according to claim 30 wherein the organism is a human.